12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Humira adalimumab regulatory update

FDA's Arthritis Advisory Committee will meet on July 23 to discuss an sBLA from AbbVie for Humira adalimumab to reduce signs and symptoms in adult patients with active non-radiographic axial spondyloarthritis who have had an inadequate...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >